10-Q/APeriod: Q1 FY2013

ALNYLAM PHARMACEUTICALS, INC. Quarterly Report (Amendment) for Q1 Ended Mar 31, 2013

Filed July 26, 2013For Securities:ALNY

Summary

This amended 10-Q filing from Alnylam Pharmaceuticals, Inc. for the quarter ended March 31, 2013, primarily serves to provide an updated Exhibit 10.2, a License and Collaboration Agreement with The Medicines Company dated February 3, 2013. Investors should note that this amendment does not alter the financial performance or operational updates previously reported in the original filing of May 7, 2013. The core financial and business disclosures remain as previously filed. While specific financial figures for the quarter are not detailed in this amendment, the filing confirms Alnylam's status as an accelerated filer. Investors interested in the specifics of the collaboration with The Medicines Company will need to review the revised Exhibit 10.2, which has undergone confidential treatment for certain sections, indicating the sensitive nature of the agreement's terms. The overall focus of this amendment is on regulatory compliance and the clarification of contractual documentation rather than reporting new financial results.

Financial Highlights

39 data points
Beta

Net Income

-$9.01M

EPS (Diluted)

$-0.15

Total Assets

$471.58M

Cash & Equivalents

$97.80M

Free Cash Flow

-$2.77M

Financial Statements
Beta
R&D Expenses$22.18M
Operating Expenses$28.45M
Operating Income-$9.80M
Net Income-$9.01M
EPS (Basic)$-0.15
Shares Outstanding (Basic)59.17M

Key Highlights

  • 1Amendment No. 1 to the Form 10-Q for the period ended March 31, 2013, filed on July 26, 2013.
  • 2The sole purpose of this amendment is to provide a revised Exhibit 10.2, a License and Collaboration Agreement with The Medicines Company, dated February 3, 2013.
  • 3This amendment does not modify or update any other portion of the original Form 10-Q filing.
  • 4Certain portions of the License and Collaboration Agreement are subject to confidential treatment.
  • 5Alnylam Pharmaceuticals, Inc. is classified as an accelerated filer.
  • 6The filing confirms the number of outstanding common shares as of April 30, 2013, was 62,171,037.
  • 7The amendment emphasizes regulatory compliance and procedural updates rather than new financial performance disclosures.

Frequently Asked Questions

The main reason for this amended 10-Q filing is to provide a revised copy of Exhibit 10.2, which is a License and Collaboration Agreement between Alnylam Pharmaceuticals, Inc. and The Medicines Company, dated February 3, 2013. This revision was made in response to comments from the SEC in connection with a confidential treatment request.

No, this amendment (Amendment No. 1) does not contain updated financial results or any other new disclosures. It specifically states that it does not change any other portion of the original filing and does not reflect events occurring after the original filing date.

The License and Collaboration Agreement with The Medicines Company, dated February 3, 2013, is a significant document for Alnylam. While the specific terms are partially confidential, such agreements typically outline research, development, and commercialization rights and responsibilities for specific drug candidates, often involving upfront payments, milestone payments, and royalties, representing a key strategic partnership.

Based on this filing, Alnylam Pharmaceuticals, Inc. is classified as an accelerated filer. This classification generally indicates that the company meets certain size and filing history requirements, suggesting it is a well-established public company, but not necessarily a 'large accelerated filer' which has higher thresholds.